Literature DB >> 478640

Efficacy of antimicrobial therapy in experimental rat pneumonia: effects of impaired phagocytosis.

I A Bakker-Woudenberg, J Y de Jong-Hoenderop, M F Michel.   

Abstract

The importance of intact host defense mechanisms for successful antimicrobial therapy was investigated in an animal model. Recovery from lobar pneumococcal pneumonia as a result of penicillin therapy was studied in normal rats and in rats treated with cobra venom factor. This factor was used to selectively suppress the phagocytosis of pneumococci as a result of complement depletion. Although complete recovery from the infection occurred in normal rats after appropriate penicillin therapy, this was not the case in cobra venom factor-treated rats. Within the limitations of this study, evidence is presented for loss of antibiotic activity as a consequence of impaired phagocytosis.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 478640      PMCID: PMC414461          DOI: 10.1128/iai.25.1.366-375.1979

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  39 in total

1.  Activation of the alternative pathway by pneumococcal cell walls.

Authors:  J A Winkelstein; A Tomasz
Journal:  J Immunol       Date:  1977-02       Impact factor: 5.422

2.  Classical and alternative complement pathway activation by pneumococci.

Authors:  C G Stephens; R C Williams; W P Reed
Journal:  Infect Immun       Date:  1977-08       Impact factor: 3.441

3.  The clinical implications of hypogammaglobul inemia in patients with chronic lymphocytic leukemia and lymphocytic lymphosarcoma.

Authors:  J E ULTMANN; W FISH; E OSSERMAN; A GELLHORN
Journal:  Ann Intern Med       Date:  1959-09       Impact factor: 25.391

4.  The effect of complement depletion on lung clearance of bacteria.

Authors:  G N Gross; S R Rehm; A K Pierce
Journal:  J Clin Invest       Date:  1978-08       Impact factor: 14.808

5.  The ability of smooth and rough strains of Streptococcus pneumoniae to activate human complement by the alternative pathway.

Authors:  M Edwards; J M Stark
Journal:  J Med Microbiol       Date:  1978-02       Impact factor: 2.472

6.  Infections in patients with malignant lymphoma treated with combination chemotherapy.

Authors:  R Feld; G P Bodey
Journal:  Cancer       Date:  1977-03       Impact factor: 6.860

7.  An experimental analysis of the curative action of penicillin in acute bacterial infections. II. The role of phagocytic cells in the process of recovery.

Authors:  M R SMITH; W B WOOD
Journal:  J Exp Med       Date:  1956-04-01       Impact factor: 14.307

8.  Efficacy of antimicrobial therapy in experimental rat pneumonia: antibiotic treatment schedules in rats with impaired phagocytosis.

Authors:  I A Bakker-Woudenberg; A L van Gerwen; M F Michel
Journal:  Infect Immun       Date:  1979-07       Impact factor: 3.441

9.  The role of membrane receptors for C3b and C3d in phagocytosis.

Authors:  A G Ehlenberger; V Nussenzweig
Journal:  J Exp Med       Date:  1977-02-01       Impact factor: 14.307

10.  Host-parasite relationships in experimental pneumonia due to pneumococcus type III.

Authors:  W B WOOD; M R SMITH
Journal:  J Exp Med       Date:  1950-07-01       Impact factor: 14.307

View more
  16 in total

1.  Emergence of resistant Klebsiella pneumoniae in the intestinal tract during successful treatment of Klebsiella pneumoniae lung infection in rats.

Authors:  Anne-Sylvie Kesteman; Agnès Perrin-Guyomard; Michel Laurentie; Pascal Sanders; Pierre-Louis Toutain; Alain Bousquet-Mélou
Journal:  Antimicrob Agents Chemother       Date:  2010-05-10       Impact factor: 5.191

Review 2.  The immune response and antibacterial therapy.

Authors:  Olachi Anuforom; Graham R Wallace; Laura V Piddock
Journal:  Med Microbiol Immunol       Date:  2014-09-05       Impact factor: 3.402

3.  In vitro killing of erythromycin-exposed group A streptococci by polymorphonuclear leukocytes.

Authors:  H Pruul; B Wetherall; P McDonald
Journal:  Eur J Clin Microbiol       Date:  1986-08       Impact factor: 3.267

4.  Low or high doses of cefquinome targeting low or high bacterial inocula cure Klebsiella pneumoniae lung infections but differentially impact the levels of antibiotic resistance in fecal flora.

Authors:  Maleck V Vasseur; Michel Laurentie; Jean-Guy Rolland; Agnès Perrin-Guyomard; Jérôme Henri; Aude A Ferran; Pierre-Louis Toutain; Alain Bousquet-Mélou
Journal:  Antimicrob Agents Chemother       Date:  2014-01-06       Impact factor: 5.191

5.  Influence of inoculum size and marbofloxacin plasma exposure on the amplification of resistant subpopulations of Klebsiella pneumoniae in a rat lung infection model.

Authors:  Anne-Sylvie Kesteman; Aude A Ferran; Agnès Perrin-Guyomard; Michel Laurentie; Pascal Sanders; Pierre-Louis Toutain; Alain Bousquet-Mélou
Journal:  Antimicrob Agents Chemother       Date:  2009-09-08       Impact factor: 5.191

Review 6.  Animal models of Streptococcus pneumoniae disease.

Authors:  Damiana Chiavolini; Gianni Pozzi; Susanna Ricci
Journal:  Clin Microbiol Rev       Date:  2008-10       Impact factor: 26.132

7.  Therapeutic activities of cefazolin, cefotaxime, and ceftazidime against experimentally induced Klebsiella pneumoniae pneumonia in rats.

Authors:  I A Bakker-Woudenberg; J C van den Berg; M F Michel
Journal:  Antimicrob Agents Chemother       Date:  1982-12       Impact factor: 5.191

8.  Efficacy of continuous versus intermittent administration of penicillin G in Streptococcus pneumoniae pneumonia in normal and immunodeficient rats.

Authors:  I A Bakker-Woudenberg; J C van den Berg; P Fontijne; M F Michel
Journal:  Eur J Clin Microbiol       Date:  1984-04       Impact factor: 3.267

9.  Comparative role of complement in pneumococcal and staphylococcal pneumonia.

Authors:  J D Coonrod; K Yoneda
Journal:  Infect Immun       Date:  1982-09       Impact factor: 3.441

10.  Enhancement of the local inflammatory response to bacterial infection by muramyl dipeptide.

Authors:  P M Lamont; G R Schrodt; R B Galland; C M Kaufman; W G Cheadle; H C Polk
Journal:  Br J Exp Pathol       Date:  1984-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.